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ABSTRACT 
INTRODUCTION: Lymphatic mapping and sentinel lymphadenectomy 
(LM/SL) is considered the nodal staging procedure of choice for patients with 
intermediate thickness (> 1.0mm, <4.0mm) melanoma. Despite this, the procedure 
has not been universally adopted. The aims of this investigation are to document 
the prevalence of LM/SL utilization and to identifY predictors of under use. I METHODS: All incident cases of melanoma from 1999-2001 reported to the 
North Carolina Central Cancer Registry (CCR) were examined. Subjects who had 
primary tumors> l.Omm and <4.0mm thick and no clinical evidence of nodal or 
distant metastases were considered eligible for LM/SL. Bivariate and multivariate 
logistic regression analysis was performed to identifY factors associated with 
receipt of LM/SL. 
RESULTS: There were 3436 incident cases of melanoma reported for 1999-2001 
(1111 in 1999, 1089 in 2000, and 1236 in 2001). 273 cases (8%) were excluded 
from analysis due to distant metastases or palpable adenopathy. An additiona1916 L 
(29%) cases were excluded because the T classification of the primary tumor was 
not reported. Of the remaining 2247 cases, 1242 (55%) were eligible for LM/SL 
(T2 or T3), of which 48.0% (596/1242) underwent LM/SL. The proportion of 
subjects undergoing LM/SL was significantly associated with year of diagnosis 
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(44% in 1999, increasing to 52% in 2000 and 50% in 2001, p=0.05). Subjects 60 
years and older were less likely to undergo LM/SL compared to subjects less than 
60 years (39% vs. 55%, p<O.OOl ). Subjects with head or neck primary tumors 
were significantly less likely to undergo LM/SL compared to subjects with trunk 
or extremity primaries (32.9% vs. 51.4% and 51.9%, respectively, p<O.OOl), and 
subjects with T2 lesions were less likely to receive LM/SL than subjects with T3 
lesions (41.7% vs. 53.6%, p<O.OOl). All of the associations remained statistically 
significant on multivariate analysis. 
CONCLUSION: Half of all eligible melanoma patients in North Carolina are 
failing to receive LM/SL. Predictors of underutilization of LM/SL include thinner 
primary tumors, advanced age, and head/neck location of the primary tumor. 
Further investigation is warranted to explore these differences and to improve 
utilization. 
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INTRODUCTION 
Since most melanoma care occurs in the outpatient setting, documenting 
the incidence of melanoma is very difficult. 1-3 Documenting the diagnostic and 
treatment options offered to patients with melanoma is even more problematic. 
Single- or even multi-institution studies of melanoma do not provide information 
about cases that are managed in the offices of community physicians, in 
outpatient surgical centers, or even in small community hospitals. As a result, 
there is a paucity of information about the care delivered to melanoma patients in 
the United States. To understand the diagnostic and treatment options used for 
patients with melanoma requires a population-based approach. 
Lymphatic mapping and sentinel lymphadenectomy (LM/SL) is a good 
example of a diagnostic option for which little is know about actual utilization for 
patients with melanoma. LM/SL has become the nodal staging procedure of 
choice for patients with intermediate thickness melanoma.4-6 LM/SL provides 
important staging information and identifies which patients may benefit from 
adjuvant therapy or clinical trials. However, to date, only one study has attempted 
to document the utilization ofLM/SL for melanoma.7 Examining Surveillance, 
Epidemiology and End Results (SEER) data, Baxter and Tuttle found that only 
4 7% of patients diagnosed with an intermediate thickness melanoma (Breslow 
thickness :::>:l.OOmm) underwent LM/SL between 1998 and 2000. 
Three broad categories of factors that influence the receipt of optimal 
cancer care have been described: structural factors, physician/clinical factors and 
patient factors. 8 Physician/clinical factors are those factors that may influence 
4 
! 
!. 
i 
I 
physician decision-making and physician recommendations. This study will 
examine how various physician/clinical factors may influence incorporation of 
LM/SL into the care of patients with intermediate thickness melanoma in North 
Carolina. We hypothesize that a significant portion of eligible patients are not 
receiving any surgical nodal staging and that certain factors, including patient age 
and location of the primary tumor, significantly influence whether a patient 
undergoes LM/SL. 
METHODS 
The North Carolina Central Cancer Registry (CCR) is a comprehensive 
I state tumor registry, managed by the North Carolina State Center for Health Statistics. The CCR collects data on all cancer cases diagnosed among North 
Carolina residents through mandatory reporting. North Carolina law(§ 130A-209) 
requires that "All health care facilities and health care providers that detect, 
diagnose, or treat cancer shall report to the central cancer registry each diagnosis 
of cancer in any person who is screened, diagnosed, or treated by the facility or 
provider." Hospitals are the primary sources of data for the CCR. These data are 
then supplemented with data from private physicians and pathology laboratories 
and with information obtained from death certificates. All incident cases of 
melanoma between January 1, 1999 and December 31,2001 reported to the CCR 
before February 2004 were analyzed for this study. 
Cases in which there was any indication of distant metastasis or palpable 
adenopathy at the time of diagnosis were excluded. The remaining cases were 
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categorized by reported T classification [American Joint Committee on Cancer 
(AJCC) Staging Manual, 5th edition].9 T1 (Breslow thickness :s;0.75mm) and T4 
(Breslow thickness >4.0mm) cases were excluded from the analysis as LM/SL 
would not have been universally recommended for these cases. Cases that did not 
have a reported T classification were also excluded. As a result, cases that were 
considered "eligible" for LM/SL included all subjects who had a reported T 
classification of T2 or T3 and no reported clinical evidence of nodal or distant 
metastasis at the time of diagnosis. 
The proportion of eligible cases that received LM/SL was calculated. 
Cases were considered to have received LM/SL ifLM/SL was ever attempted. 
Consequently, cases in which LM/SL was performed and followed with 
completion lymph node dissection, either immediately or as part of a second 
procedure, were considered to have received LM/SL. Additionally, cases in 
which LM/SL was attempted, but no sentinel node was identified, were also 
considered to have received LM/SL. 
Some patients received other, unspecified nodal staging procedures. 
These cases may have included elective lymph node dissections, LM/SL that were 
not coded as such, or other nodal sampling procedures. To maximize sensitivity 
for nodal staging, the proportion of eligible cases who received any type of nodal 
staging procedure was also calculated. Subjects were considered to have received I 
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a nodal staging procedure if they underwent LM/SL, ELND, or any other type of 
lymph node biopsy or sampling. 
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The relationships between receipt of LM/SL and multiple clinical, 
histopathologic, and demographic factors that may have affected physician 
decision-making were examined. Bivariate analysis was performed using the 
Pearson's chi-square test for categorical variables and logistic regression for 
continuous variables (Stata 8.2, StataCorp, College Station, Texas). Race was 
dichotomized due to the small number of African-American, Hispanic, Asian, and 
Native American subjects, and Fisher's Exact test was used, since very few non-
White subjects were eligible for LM/SL. The associations were confirmed using 
multivariate logistic regression, incorporating all factors into the model. 
Pearson's chi-square, Fisher's Exact, and logistic regression were also used to 
examine the relationships between receipt of any nodal staging procedure and the 
various clinical, histopathologic, and demographic factors. 
T classification was used to define eligibility for LM/SL, since actual 
Breslow thickness was only available for a subset of the cases (821/3436). 
Relying on categorization by T classification required "eligible" cases to be 
defined as those with a Breslow thickness 0.76-4.00mm. However, use ofLM/SL 
is controversial for cases with a Breslow thickness between 0. 75mm and 
1.00mm.10•19 As a result, the analysis was repeated for the subset of patients for 
whom Breslow thickness was known in order to validate the main analysis. For 
the subset analysis, "eligible" cases were limited to those with a Breslow 
thickness 1.00mm-4.00mm. 
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The study protocol was approved by the North Carolina Central Cancer 
Registry and by the University of North Carolina School of Medicine Institutional 
Review Board. 
RESULTS 
There were 3436 incident cases of melanoma in North Carolina between 
1999 and 2001: 1111 in 1999, 1089 in 2000, and 1236 in 2001. Overall, there 
were 1948 (56.7%) men and 1488 (43.3%) women with a mean age for the cohort 
of57.3 years (SD+/-17.3 years). 97.7% (3356/3436) of subjects were White. The 
primary site was reported as head or neck in 721 (21. 0%) cases, trunk in 1129 i 
I (32.9%) cases, extremity in 1373 (40.0%) cases, and other or unknown in 213 (6.2%) cases. 
273 cases (8%) were excluded from analysis due to distant metastasis 
(192), palpable adenopathy (57), or both (24). T classification was not available 
for 916 (29%) cases. Of the remaining 2247 cases, 1242 (55%) were eligible for 
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1 LM/SL (T2 or T3). 
Overall, 48.0% (596/1242) of eligible subjects received LM/SL. Use of 
LM/SL increased slightly over the three years. Table 1. The increase from 1999 
to 2000 was statistically significant (p=0.021). Subjects with head or neck 
primary tumors were significantly less likely to receive LM/SL compared to 
subjects with trunk or extremity primaries (32.9% vs. 51.4% and 51.9%, 
respectively, p<0.001). Additionally, subjects with T3 lesions were more likely to 
receive LM/SL than subjects with T2lesions (53.6% vs. 41.7%, p<0.001). 
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Although males (49.2%) and Whites (48.2%) were more likely to receive LM/SL 
than females (46.3%) and non-Whites (34.8%), these differences were not 
statistically significant on bivariate analysis. 
When age was examined as a continuous variable, there was a significant 
association between diagnosis age and receipt ofLM/SL (OR 0.979, 95% CI 
0.972, 0.985) Figure 1 demonstrates that use ofLM/SL begins to drop off 
significantly as early as the sixth decade. 39.3% of subjects 60 years of age or 
older received LM/SL compared to 55.4% of subjects less than 60 years of age 
(p<0.001). Even when the very young (<20 years) and very old (>84 years) were 
excluded, the difference remained highly statistically significant ( 41.2% vs. 
On multivariate analysis, the associations between receipt of LM/SL and I 55.1%, p<0.001). 
diagnosis year, primary site, T classification, and diagnosis age remained 
significant. Table 2. In addition, after adjusting for the other variables, although 
still small, the difference between males and females was statistically significant 
(OR for males 1.35, 95% CI 1.05, 1.73). 
The proportion of cases that received any type of nodal staging procedure 
was also examined. Figure 2. Overall, 692 (55.7%) of the 1242 eligible subjects 
received some type of nodal staging procedure; 596 (86.1%) received LM/SL and 
96 (13.9%) received another, unspecified type of nodal staging procedure. In 
general, the factors that were significantly associated with receipt of LM/SL were 
also associated with receipt of any nodal staging procedure. Table 1. 
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When the analysis was limited to those subjects who received a nodal 
staging procedure, primary site was the only factor significantly associated with 
receipt ofLM/SL (p=0.002). Figure 3. Subjects with trunk lesions were the most 
likely to receive LM/SL, while subjects with head or neck primary tumors were 
the most likely to receive a nodal staging procedure other than LM/SL. Even 
after adjusting for the other factors, subjects with a head or neck primary tumor 
who underwent nodal staging were significantly less likely to have received a 
LM/SL (p<0.001). Table 3. 
Since the utility of LM/SL for patients with a Breslow thickness between 
0. 75rnm and 1.00rnm is controversial, 19 the analysis was repeated using the 
reported Breslow thickness to defme eligibility for LM/SL. A reliable Breslow 
thickness was available for 23.9% (821/3436) of all cases. Forty-five (5.5%) i 
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subjects were excluded for distant metastasis or palpable adenopathy at diagnosis. 
Of the remaining 776 cases, 282 (36.3%) were eligible for LM/SL (Breslow 
thickness :0:1.00 and ::;4.00rnm). 41.8% (118/282) of these cases underwent 
LM/SL. An additional 19 ( 6. 7%) cases underwent some other type of nodal 
staging procedure. While the proportions of subjects who received LM/SL by 
primary site, diagnosis year, and T classification were comparable to those found 
for the whole group analysis, these associations were not statistically significant 
for the subset. Tables 4 and 5. In contrast, the association between receipt of 
L 
LM/SL and diagnosis age was again highly statistically significant on multivariate 
analysis (p<0.001). 
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DISCUSSION 
LM/SL is regarded as the nodal staging procedure of choice for patients 
with intermediate thickness melanoma,4• 6 yet roughly half of eligible patients do 
not receive the procedure.7 Consistent with Baxter and Tuttle's experience using 
SEER data, we found that only 48% of eligible subjects underwent LM/SL in 
North Carolina between 1999 and 2001. Three categories of factors (structural, 
physician/clinical, and patient) may influence receipt of optimal cancer care.8 
This study examined several physician/clinical factors that may influence 
physician decision-making, including depth of the primary tumor, patient gender, 
primary site, patient race, and patient age. Additionally, diagnosis year, which 
could be viewed as a structural factor, was examined. 
Increasing Breslow thickness is known to be associated with an increasing 
risk of recurrence and death.2° Consequently, depth of the primary tumor may 
influence physician decision-making. Subjects with T2 lesions (Breslow 
thickness 0. 76-l.50mm) were less likely to receive nodal staging procedures than 
subjects with T3 lesions (Breslow thickness l.51-4.00mm), suggesting that 
physicians may be less likely to endorse LM/SL for less advanced lesions. 
In contrast, although older age has been suggested to be a risk factor for 
poor prognosis in patients with melanoma, 21• 22 older adults were less likely to 
receive nodal staging even after adjusting for other factors. Use ofLM/SL was 
uniform among adults less than 50 years of age. However, after age 50, the use of 
nodal staging dropped off steadily. It is understandable that LM/SL might not be 
offered to the very old, who would not be eligible for clinical trials and may not 
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be able to tolerate additional surgical procedures or chemotherapeutic regimens. 
However, for adults in their 50s, 60s, and 70s, the reason for decreased utilization 
is not as clear. 
Subjects with head or neck primary tumors were also less likely to receive 
nodal staging. Not only were nodal staging procedures, in general, less common 
for this group, but among patients who did receive a nodal staging procedure, 
subjects with head or neck primary tumors were far less likely to receive LM/SL 
than subjects with trunk or extremity primary tumors. This difference deserves 
further exploration. 
Although we did not have information on the specialty of the primary 
surgeon, we suspect that the training of the primary surgeon may be an important 
factor impacting physician decision-making and leading to this difference. 
LM/SL of the head and neck is technically more difficult than in other regions due 
to the variability in lymphatic drainage patterns.23 It is likely that most general 
surgeons are not as comfortable with nodal dissections of the head and neck as 
they are with dissections of the axilla and groin. As a result, subjects with head 
and neck primary melanomas who are managed by general surgeons may be Jess 
likely to receive nodal staging. Alternatively, since otolaryngologists are less 
likely to have been trained to perform LM/SL, they may be more likely to 
perform a nodal staging procedure other than LM/SL on their patients with 
melanoma. While this is simply speculation, further investigation into the factors 
contributing to the decreased use ofLM/SL in patients with head or neck primary 
tumors is warranted. 
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With only three time points, we were unable to demonstrate an increase in 
utilization over time. While there was a significant increase in the utilization of 
LM/SL between 1999 and 2000, a similar increase was not seen from 2000 to 
2001. Similarly, Baxter and Tuttle demonstrated an increase in use ofLM/SL 
from 1998 to 1999 ( 40% to 50%), but were unable to show a consistent trend. 7 
Limitations 
This analysis was limited by the fact that T classifications had to be used 
to determine eligibility for LM/SL. Although Breslow thickness is more precise a 
reliable Breslow thickness was only available for a subset of cases, all of which 
were reported by a certain subset of facilities. As a result, using Breslow 
thickness would have led to a systematic selection bias. For a true population-
based analysis, T classifications were felt to be more appropriate. The drawback 
of using T classifications is that staging recommendations from the AJCC Staging 
Manual, 5th Edition9 were in effect during this time period, so T2 and T3 lesions 
included all lesions 0.76mm-4.0mm thick. Consensus regarding the utility of 
LMISL is limited to lesions 1.00mm-4.00mm thick.19 As a result, relying on T 
classifications potentially could have resulted in underestimation of the use of 
LM/SL for cases with Breslow thickness 1.00mm-4.00mm. However, utilization 
of LMISL in the subset analysis was even lower than in the main analysis, despite 
using Breslow thickness of 1.00mm as the lower limit of eligibility,. 
Consequently, we do not feel that inclusion of primary tumors of Breslow 
thickness 0. 76mm-1.00mm in the main analysis significantly impacted our results. 
l3 
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When working with population-based cancer registries, there is always 
concern about the completeness of the data. This is particularly true for 
melanoma, since complete case ascertainment for melanoma has historically been 
difficult. I-J Incomplete reporting of first course of treatment information could 
have led to underestimation of the use of nodal staging procedures. However, our 
results were consistent with the previous analysis of SEER data, 7 and the North 
Carolina CCR has been certified by the North American Association of Central 
Cancer Registries every year since 1997, establishing a track record of complete 
case ascertainment. 24 As a result, we do not feel incomplete data collection led to 
vast underestimation of the use of LM/SL. 
CONCLUSION 
Despite growing acceptance of LM/SL as the nodal staging procedure of 
choice for patients with intermediate thickness melanoma, only about half of 
eligible patients are currently receiving the procedure. Older patients and those 
with head or neck primary tumors are the least likely to receive LM/SL. Further 
research is warranted to explain these differences and to examine other structural, 
physician/clinical, or patient factors that may impact the use of LM/SL. 
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FIGURE 1. Use ofLM/SL by age at diagnosis. 
100 
90 r----
80 ··-
-' i 70 
-' 
g> 
:i!: 60 ~ 
' 
""' 
....... 
.... 
.,... 
I 50 
" 
"' 
40 ---- -
~ 
0 
-
c 
~ 30 
d?. 
20 !---· 
10 r--
0 
0-19 20-29 30-39 40-49 
----
......_ 
50-59 
Diagnosis Age 
~ 
60-69 
·-----
~ 
·-
' 
"' ~ 
70-79 80-89 90-100 
•'~"'"" 'T'' ""~·- "''"·••-•w"'" "'·'~'"·<·'"''"''"" """"'"'' ''""''''""''''"-'"'1"1•~<t·•" "'~·-·• "•w•"'''""'111-lll'l'''~'llm~l'1"'"'''' ""''·'•~·-' ""«'»"'"'~~-" ,, "'' -' · ······• ""~''"'" 
15 
FIGURE 2. Summary of All Nodal Staging Procedures by Diagnosis Year. 
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Figure 3. S=ary of All Nodal Staging Procedures by Primary Site. 
100.0% 
90.0% 
I!! 
" "C 80.0% .. 
u 
e 
70.0% a. 
"' c :~ 60.0% 
.. 
u 
& 50.0% 
~ 
.. 40.0% :c' 
" 
"' 0 30.0% 
c 
.. 20.0% !:? 
.. 
a. 
10.0% 
0.0% 
Head or Neck 
"''"~"~"'"'"' ., '"' !'""""'' ,, ">"•"·~--""'''"''' '" ,_,,_,,.~ ,.,., •. ; ''"''""'' 
Trunk 
Primary Site 
Extremity 
11111 LM/SL 1111 Other Nodal Staging Procedu~ 
"~- "''l"'''f>"'-"" "!IIBIIIIII'IIi'~"l"!ii~f1'i>'0''" '"'"""'"""'-"""'"''"'';' '~"'"""'"'" ' "'"''"''" •-»wv•• 
17 
'"I''''" •··t•·· ··<>•-·""'l'"·~,-~-r"""-
TABLE 1. Bivariate analysis of receipt of nodal staging among subjects with T2 or T3 (AJCC Staging Manual, 5'h edition9) primary 
0.312 0.110 
<0.001 <0.001 
0.201 0.442 
<0.001 <0.001 
<0.001 <0.001 
0.051 0.118 
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TABLE 4. Bivariate analysis of receipt of nodal staging procedures among subjects with a primary tumor Breslow thickness 
1.00mm-4.00mm (n=282 
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